By Chris Wack

Beam Therapeutics Inc. said Friday that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.

The biotechnology company said its BEAM-201 is a specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

"The FDA's clearance of our IND for BEAM-201 is an exciting moment for Beam and for the field of gene editing, as it represents the first IND clearance for a multiplex-base edited investigational drug," said John Evans, chief executive of Beam.

Beam shares were up 11% to $51 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 02, 2022 06:55 ET (11:55 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024 Beam Therapeutics 차트를 더 보려면 여기를 클릭.
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024 Beam Therapeutics 차트를 더 보려면 여기를 클릭.